Piramal Healthcare shines on plans to acquire molecular imaging portfolio of Bayer

16 Apr 2012 Evaluate

Piramal Healthcare is currently trading at Rs. 460.75, up by 10.40 points or 2.31% from its previous closing of Rs. 450.35 on the BSE.

The scrip opened at Rs. 453.50 and has touched a high and low of Rs. 462.05 and Rs. 452.20 respectively. So far 1,265 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 562.50 on 02-Apr-2012 and a 52 week low of Rs. 340.00 on 30-Nov-2011.

Last one week high and low of the scrip stood at Rs. 470.00 and Rs. 449.00 respectively. The current market cap of the company is Rs. 9,876.00 crore.

The promoters holding in the company stood at 53.08% while Institutions and Non-Institutions held 25.97% and 20.95% respectively.

Piramal Healthcare (Piramal) has signed an agreement to acquire worldwide rights to the molecular imaging research and development portfolio of Bayer Pharma AG (Bayer) through its newly created subsidiary - Piramal Imaging SA. The portfolio includes rights to florbetaben, which is in the final stages of its Phase III clinical trials. First Phase III results will be presented in New Orleans at the American Academy of Neurology Annual Meeting on April 25, 2012.

As per the agreement, Piramal will have the intellectual property (including patents, trademarks and know-how), worldwide development, marketing and distribution rights of the lead compound florbetaben as well as other clinical and pre-clinical assets of Bayer’s molecular imaging business.

Besides, the core members of Bayer’s research and development team working on the portfolio will be joining Piramal Imaging, which will carry forward the development of florbetaben and take it through regulatory approval processes worldwide. Piramal is planning to file for regulatory approvals in 2012.

Florbetaben is a PET tracer for the detection of beta-Amyloid plaque deposition in the brain, which is the pathological hallmark of disease in probable Alzheimer’s disease patients. Detection of beta-Amyloid depositions is expected to result in earlier diagnosis and more specific treatment of Alzheimer’s disease.

The Phase III trial showed that PET imaging with florbetaben reliably detects beta-amyloid in the brain during life with great accuracy and thus shows value as a potential tool to aid in the diagnosis and assessment of Alzheimer’s disease.

 

Piramal Ent - Amalga Share Price

1124.60 0.00 (0.00%)
22-Sep-2025 16:59 View Price Chart
Peers
Company Name CMP
Bajaj Finance 904.35
Shriram Finance 962.20
Aditya Birla Capital 333.10
Chola Invest & Fin. 1595.65
Tata Capital 331.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×